Autolus Therapeutics plc
AUTL
$1.75
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.93M | 9.01M | 10.12M | 10.09M | 10.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.93M | 9.01M | 10.12M | 10.09M | 10.50M |
| Cost of Revenue | 210.18M | 185.26M | 171.24M | 150.27M | 150.58M |
| Gross Profit | -180.25M | -176.24M | -161.12M | -140.18M | -140.08M |
| SG&A Expenses | 129.61M | 121.25M | 109.89M | 91.31M | 74.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 299.91M | 276.28M | 250.91M | 228.29M | 203.56M |
| Operating Income | -269.97M | -267.27M | -240.79M | -218.20M | -193.07M |
| Income Before Tax | -223.67M | -234.37M | -219.14M | -270.19M | -233.98M |
| Income Tax Expenses | 4.11M | 3.76M | 1.53M | 41.00K | -2.00K |
| Earnings from Continuing Operations | -227.78 | -238.13 | -220.66 | -270.23 | -233.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -227.78M | -238.13M | -220.66M | -270.23M | -233.98M |
| EBIT | -269.97M | -267.27M | -240.79M | -218.20M | -193.07M |
| EBITDA | -261.31M | -259.08M | -233.07M | -210.78M | -186.21M |
| EPS Basic | -0.86 | -0.89 | -0.87 | -1.21 | -1.16 |
| Normalized Basic EPS | -0.52 | -0.55 | -0.54 | -0.75 | -0.72 |
| EPS Diluted | -0.86 | -0.89 | -0.87 | -1.21 | -1.16 |
| Normalized Diluted EPS | -0.52 | -0.55 | -0.54 | -0.75 | -0.72 |
| Average Basic Shares Outstanding | 1.06B | 1.06B | 1.02B | 928.38M | 836.28M |
| Average Diluted Shares Outstanding | 1.06B | 1.06B | 1.02B | 928.38M | 836.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |